INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. PNT (the “Company” or “POINT”), a company accelerating the discovery, development and global access of life-changing radiopharmaceuticals, today announced that it presented efficacy and safety data at the 2022 ESMO Congress in Paris, France published by PNT2002 is the lead-in cohort of the SPLASH study. An abstract is now available on the ESMO Congress website at https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal_2/presentation/list?q=1400Pand an e-poster with updated dates will be published and presented on Sunday, September 11thth.
The poster is titled “Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH” (e-Poster #1400P) and is scheduled to be presented on Sunday, September 11 from 9:00 a.m. to 5:00 p.m. CEST (Paris) by Dr. Aaron R. Hansen, Medical Oncologist at Princess Alexandra Hospital and Associate Professor of Medicine at the University of Toronto.
Prior to the publication of the abstract, the company recently hosted a 45-minute webinar entitled “Understanding the PNT2002 SPLASH Trial Control Arm”. A recording of the webinar is available online at https://hub.pointbiopharma.com/controlarm.
About the SPLASH study
The Phase 3 SPLASH study is a multicenter, randomized, open-label evaluation of PNT2002 in participants with PSMA-expressing mCRPC who have progressed on androgen receptor pathway inhibitor (ARPI) therapy and are refusing or not undergoing chemotherapy come into question. Approximately 400 participants from North America, Europe and the United Kingdom are expected to be enrolled in the randomization phase of the study. Participants will be randomized 2:1, with participants in Arm A receiving PNT2002 and participants in Arm B receiving either abiraterone or enzalutamide. Participants in Arm B who received centrally assessed radiological…
